Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Washington University School of Medicine
Summary
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Criteria for Pre-Screening Blood Draw * Newly diagnosed multiple myeloma (either untreated or receiving first line therapy). * Potentially eligible for autologous hematopoietic cell transplant (with or without tandem transplant) for frontline therapy. Inclusion Criteria: * At least 18 years of age * Ability to understand and willingness to sign an IRB approved written informed consent document. (Legally authorized representatives may sign and give informed consent on behalf of study participants.) * Received autologous hematopoietic cell transplantation (with or without tandem transplant) a…
Interventions
- DrugElrantamab
\- Elranatamab will be dosed in 28-day cycles as follows: * C1D1: 12 mg SC priming dose * C1D3: 32 mg SC priming dose * C1D8, C1D15, C1D22: 76 mg SC * Cycle 2-Cycle 7: 76 mg SC on D1 and D15 * Cycle 8 and subsequent cycles: 76 mg SC on D1
- DeviceclonoSEQ
FDA approved MRD testing
Location
- Washington University School of MedicineSt Louis, Missouri